Gene expression profiling of gliomas strongly predicts survival

被引:570
作者
Freije, WA
Castro-Vargas, FE
Fang, ZX
Horvath, S
Cloughesy, T
Liau, LM
Mischel, PS
Nelson, SF
机构
[1] Univ Calif Los Angeles, Ctr Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Henry E Singleton Brain Tumor Program, Los Angeles, CA 90095 USA
[7] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Neurosurg, Los Angeles, CA 90095 USA
[8] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA
关键词
D O I
10.1158/0008-5472.CAN-04-0452
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In current clinical practice, histology-based grading of diffuse infiltrative gliomas is the best predictor of patient survival time. Yet histology provides little insight into the underlying biology of gliomas and is limited in its ability to identify and guide new molecularly targeted therapies. We have performed large-scale gene expression analysis using the Affymetrix HG U133 oligonucleotide arrays on 85 diffuse infiltrating gliomas of all histologic types to assess whether a gene expression-based, histologyindependent classifier is predictive of survival and to determine whether gene expression signatures provide insight into the biology of gliomas. We found that gene expression-based grouping of tumors is a more powerful survival predictor than histologic grade or age. The poor prognosis samples could be grouped into three different poor prognosis groups, each with distinct molecular signatures. We further describe a list of 44 genes whose expression patterns reliably classify gliomas into previously unrecognized biological and prognostic groups: these genes are outstanding candidates for use in histology-independent classification of high-grade gliomas. The ability of the large scale and 44 gene set expression signatures to group tumors into strong survival groups was validated with an additional external and independent data set from another institution composed of 50 additional gliomas. This demonstrates that large-scale gene expression analysis and subset analysis of gliomas reveals unrecognized heterogeneity of tumors and is efficient at selecting prognosisrelated gene expression differences which are able to be applied across institutions.
引用
收藏
页码:6503 / 6510
页数:8
相关论文
共 72 条
  • [1] High expression of Aurora-B/Aurora and Ipl1-like midbody-associated protein (AIM-1) in astrocytomas
    Araki, K
    Nozaki, K
    Ueba, T
    Tatsuka, M
    Hashimoto, N
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2004, 67 (1-2) : 53 - 64
  • [2] INSITU HYBRIDIZATION LOCALIZES THE HUMAN PUTATIVE ONCOGENE GLI TO CHROMOSOME SUBBANDS 12Q13.3-14.1
    ARHEDEN, K
    RONNE, M
    MANDAHL, N
    HEIM, S
    KINZLER, KW
    VOGELSTEIN, B
    MITELMAN, F
    [J]. HUMAN GENETICS, 1989, 82 (01) : 1 - 2
  • [3] Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the organization of their actin cytoskeleton
    Belot, N
    Pochet, R
    Heizmann, CW
    Kiss, R
    Decaestecker, C
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2002, 1600 (1-2): : 74 - 83
  • [4] Influence of unrecognized molecular heterogeneity on randomized clinical trials
    Betensky, RA
    Louis, DN
    Cairncross, JG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) : 2495 - 2499
  • [5] Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions
    Bouterfa, H
    Darlapp, AR
    Klein, E
    Pietsch, T
    Roosen, K
    Tonn, JC
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1999, 44 (01) : 23 - 33
  • [6] Bouvier-Labit C, 1998, NEUROPATH APPL NEURO, V24, P381
  • [7] BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO
  • [8] 2-2
  • [9] Burger PC, 2002, BRAIN PATHOL, V12, P257
  • [10] Büschges R, 1999, BRAIN PATHOL, V9, P435